Introduction
Most Human Papillomavirus (HPV) infections are asymptomatic and regress in 6-18 months but persistent infection can cause cancer and anogenital warts and can result in morbidity and mortality in females and males (Forman et al. 2012; Giuliano et al. 2014) . The prevention of HPV has therefore become a prominent public health priority. Three vaccines, the bivalent (Cervarix®, GlaxoSmithKline; protecting against HPV 16/18), quadrivalent (Gardasil ® , Merck; protecting against HPV 6/11/16/18), and nonavalent (Gardasil Health Canada recommends that people receive the vaccines as school-aged children in order to provide the highest level of immunogenicity and to protect them before they become sexually active (Public Health Agency of Canada 2012). As of March 2017, all Canadian provinces and territories fund HPV school-based programs for girls, and six provinces have funded HPV vaccination for boys and three have announced that they will commence funding in September 2017 (CBC News 2017; Government of British Columbia, 2017; Government of New Brunswick, 2017).
As other jurisdictions decide whether to adopt the policy of funding HPV vaccine for boys, it is important to draw upon an understanding of the foundations of this policy change (Eggertson 2012; Stanley 2014) . A small but growing literature investigates decision-making processes in health policy and systems in low, middle and high-income countries (Greathouse et al. 2005; Koon et al. 2013) . In a systematic review of national decision-making concerning adopting new vaccines, Burchett and colleagues write, "There is a need for more research exploring decisionmaking processes for vaccine adoption, particularly considering how decisions are made, rather than merely who was involved" (Burchett et al. 2012, ii70) . To attempt to meet that need, this paper analyzes the underlying factors that have led to decisions to fund HPV vaccination for boys in Canada using a theoretical model of policy change. We use Kingdon's Multiple Streams (MS) framework to explore the policy decisions to fund HPV vaccination for boys because this
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theory offers a broad and multifaceted approach to conceptualize the issues that encourage decision-making and policy change (Kingdon 2011) .
Methodology
In 2008, Walt and colleagues commented on the absence of theoretical frameworks in health policy analysis. The authors argued that, "explicit attention to theory development could benefit public policy practice by deepening our understanding of causality and by bringing coherence to a fragmented body of knowledge"; they highlighted the utility of Kingdon's MS framework among others (Walt et al. 2008, 311 ). Kingdon's MS framework addresses how certain policies emerge on the public agenda and are considered by decision-makers while others languish (Thurber 2011 ). Kingdon's MS framework has been applied to investigate diverse issues in health policy development (Cairney 2007; Greathouse et al. 2005) . It describes policy development as occurring because of three concurrent, but independent, streams. The Problem Stream analyzes whether an issue has been identified as a problem that is amenable to human control (i.e. in this case, by examining whether HPV and its associated diseases constitute a health problem). The Policy Stream describes the suitability of the proposed solutions for a problem (i.e. by examining whether HPV vaccination of males is an appropriate policy solution in Canadian jurisdictions). Thirdly, the Politics Stream describes the political context whereby policy is determined (i.e. by examining the perspective of important stakeholders). When these three streams come together at critical junctures-a problem is recognized, a solution is developed, and political impetus arises -then a 'policy window' opens, thus creating opportunity for policy development (Kingdon 2011).
Results
(1) Problem stream: Identifying HPV as a problem for males HPV has been identified as a health problem in males. HPV is the most common Sexually
Transmitted Infection (STI) among males and females (Anic and Giuliano 2011) . HPV prevalence in men has been reported to be consistently higher than in females due to the poorer
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natural immune response men have to HPV infection compared to females ).
Individuals can be unaware that they have contracted HPV because HPV infection is often asymptomatic (Anic and Giuliano 2011) . The human papillomavirus becomes a health problem when it causes different sequela such as genital warts and cancer.
Epidemiologists have described a growing burden of HPV-associated cancers in men and have warned about the increasing incidence of anal, penile, rectal and oropharyngeal cancers (Palefsky 2010; Stanley 2012; Alemany et al. 2016) . Early research suggests that HPV is associated also with sinonasal, conjunctiva, and lacrimal sac cancer (Zhao, Guo, and Zhang 2016; Knör et al. 2015; Afrogheh et al. 2016 ) . HPV-related diseases, including precancerous lesions that require treatment and genital warts, significantly impair psychosocial wellbeing and health-related quality of life (Dominiak-Felden et al. 2013) . Moreover, the HPV-related cancer burden in males falls more heavily on an already disadvantaged group; MSM are more susceptible to HPVassociated diseases (Zou et al. 2014; Latini et al. 2014; Glick et al. 2014; Egan v. Canada 1995) .
HPV infection in sexually active heterosexual men is problematic also because males can transmit HPV to their female partners. HPV in women is responsible for cervical cancer and can cause vulvar, vaginal, anal, rectal, and oropharyngeal cancers (Palefsky 2010; Public Health Agency of Canada 2016 ). An association between HPV treatments has also been reported with miscarriage and preterm birth (Maria et al. 2015; Yang et al. 2013; Bonde et al. 2014) , though further research is required. HPV infection has been associated with a higher risk of HIV acquisition (Houlihan et al. 2012) . HPV infection can be transmitted by a pregnant woman to her foetus, resulting rarely in recurrent respiratory papillomatosis (Palefsky 2010 ).
The conditions caused by HPV in men, women and infants are largely preventable (Crosignani et al. 2013 ). However, no early detection measures are currently available to males (e.g. screening or HPV DNA testing) and not all males are included in a government funded prevention strategy (e.g. vaccination).
(2) Policy stream: Identifying HPV vaccination of males as an appropriate policy solution for
To investigate whether HPV vaccination is an appropriate policy solution, we examine the suitability, equity, acceptability, and cost-effectiveness of this solution in Canada.
Suitability. The safety of the HPV vaccines has been determined in multiple randomized controlled trials and epidemiological reviews (Ferris et al. 2014; Palefsky et al. 2011; Vichin et al. 2015) . Adverse events are rare. Most reported reactions concern pain at the injection site, which typically resolves in less than five days (Shearer 2011; Ferris et al. 2014) . Extremely rare adverse events include flu-like symptoms (e.g. fever) and anaphylaxis (Brotherton, Zuber, and Bloem 2016) .
The HPV vaccine has been shown also to be efficacious. In well-controlled trials, HPV vaccination prevented persistent infections (Ferris et al. 2014) , and the HPV vaccine has been found to confer cross-protection against other HPV strains in females (Tabrizi et al. 2014; Wheeler et al. 2012) . Recent studies have shown that the proportion of high-grade cervical intraepithelial neoplasia lesions caused by HPV 16 and 18 have declined only among women who received the HPV vaccine (Crosignani et al. 2013; Hariri et al. 2015) .
Even though there are fewer studies of the vaccines' preventative effect in males (because the vaccine was initially approved only for females), all indications are that the vaccines demonstrate comparable immunogenicity for both sexes (Hillman et al. 2012; Stillo et al. 2015) . The emerging literature on HPV vaccines in males has demonstrated the safety and non-inferior immunogenicity in males (Castellsague et al. 2015; Iversen et al. 2016; Lehtinen et al. 2016; Van Damme et al. 2015; Van Damme et al. 2016; Yang and Bracken, 2016) . Pinto et al. (2016) found that vaccinating males induces HPV antibodies in the oral cavity in the majority of males, though it is still unclear whether antibody levels will provide long-term protection against infection. We may not see a direct reduction in cancer incidence in males for a number of years because cancer is a disease of latency; however, all available evidence anticipates a decline of HPV-associated cancers in males in the future because of HPV vaccination (Ferris et al. 2014) .
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Because of its safety and efficacy profile, the HPV vaccine has been licensed by identified Shapiro et al. 2015) , including that it unfairly requires school-aged males to self-identify as homosexual to receive a health benefit. The province of Quebec has adopted an inclusive approach by funding the HPV vaccine both for
MSM (under age 26) and all boys (in Grade 4) (Gouvernement du Québec 2016).
Some researchers argue that a female only HPV vaccination policy disadvantages not only MSM, but all males who must rely on herd immunity for protection (Stanley 2012) .
Problematically, even though girls in Canada may receive the vaccine at no cost, they are not doing so at levels that adequately confer herd immunity. For example, though uptake varies by jurisdiction (e.g. 52.6% in Nunavut to 89.3% in Newfoundland and Labrador), only 72.3% of 12-
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Canadian males who have sexual relationships with partners who are, or have come from, outside Canada. A policy that requires males to rely on females for protection from HPV is not equitable. Moreover, such a policy also treats women unequally by placing the burden to protect men on women (Crosignani et al. 2013) .
Acceptability. Canadian studies report high acceptability of HPV vaccination for males. For example, a questionnaire conducted in a mid-size Ontario city revealed that mothers supported HPV vaccination for their daughters or sons (77.8% and 70.7% respectively) in their early teens;
however, mothers were less willing to consent to vaccination of their younger children, 9 or 10-year-old daughters or sons (41.5% and 38.3%) (Lenehan et al. 2008) . Ogilvie et al. (2008) examined acceptability of HPV vaccination for boys (N=1381) across Canada and found that 67.8% of Canadian parents planned to vaccinate their sons but acceptability varied (from 61.7%
in British Columbia/Yukon to 79.8% in Atlantic Canada) (Ogilvie et al. 2008 ).
In studies examining uptake after 2012 when the HPV vaccine was recommended for males in Canada, the results have been mixed. McClure et al. (2015) found uptake was high (i.e. 79%) in P.E.I. after the public program was instituted (McClure et al. 2015) . By contrast, Perez et al.
(2016) surveyed a national sample of Canadian parents at two time points (N=3117, N=1427), when only P.E.I. and Alberta funded male vaccination. These researchers found less than 3% of parents reported that their 9-16 year-old sons received the HPV vaccine. Importantly, the vast majority of parents were in the early stages of vaccination adoption suggesting that many parents did not know that HPV vaccination is recommended for boys .
A number of barriers to acceptability by parents have been identified in the literature and include not receiving a recommendation from a health professional (Newman et al. 2013) , lack of knowledge regarding the availability and recommendation of the HPV vaccine (Lenehan et al. 2008 ), negative attitudes towards vaccination (Ogilvie et al. 2008) , as well as cost and logistical issues (Newman et al. 2013 ). Adolescents may also object to the vaccine due to generic vaccination concerns such as fear of needles (Hilton et al. 2013) , or believing there is no need for HPV vaccination because they are not sexually active (Forster et al. 2012) . Some Canadians may perceive that if the government has not funded a vaccine then it is unnecessary (Scheifele et Most studies modeling cost-effectiveness have reported that vaccinating boys is less costeffective than increasing HPV uptake in females, particularly when there is moderate to high coverage in females (Brisson, Van de Velde, and Boily 2009; Brisson et al. 2011; Chesson et al. 2011; Jit et al. 2008; Pearson et al. 2014; Seto et al. 2012 ). By contrast, some studies have found male HPV vaccination to be cost-effective, particularly with lower estimated vaccine cost and greater estimated efficacy (Brisson et al. 2016; Burger et al. 2014; Elbasha and Dasbach 2010; Elbasha et al. 2007; Graham et al. 2015; Haeussler et al. 2015) . There is substantial heterogeneity in the methodology and model parameters of different cost-effectiveness analyses (Pink et al., 2017) . The main drivers of cost-effectiveness of gender-neutral vaccination has been the assumed vaccine and administration costs, whether cost reductions related to all HPVrelated diseases were considered, whether female coverage was sub-optimal, whether herd immunity effects from girls were considered, and wider socio-economic considerations (Burger et al., 2014; Crosignani et al. 2013; Olsen and Jorgensen 2015; Jiang et al. 2013; Kim et al., 2007; Kotsopoulos et al. 2015; Pearson et al., 2014) . Almost all models do not take into account Chesson et al. 2011; Laprise et al. 2014) , and HPV-related infant prematurity as a result of treatment for Cervical Intraepithelial Neoplasia (Ryser et al. 2015; Soergel et al. 2012; Olsen and Jorgensen 2015; Isidean et al. 2015) . While some of these factors have been examined by some authors, we know of no study that has modeled and assessed all these factors simultaneously.
Like Pink and colleagues, we advocate that studies report their assumptions and the impact of simplifying assumptions (Pink et al., 2017) . Further, an updated systematic review that compares and contrasts these cost-effectiveness analyses is also merited.
(3) Politics Stream: Identifying the perspective of important stakeholders
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The Politics Stream analyzes the political context and the perspectives and partisan influence of stakeholders in the decision arenas (Nowlin 2011) . Interest groups can promote or block a policy change (Kingdon 2011). Groups that have a stake in the political debate about HPV vaccination for boys in Canada include the federal and provincial governments, the scientific and medical community, civil society, the media, pharmaceutical companies and school boards.
Government. Canadian provinces and territories are responsible for providing health care to people in Canada (The Constitution Act 1867). Nevertheless, the federal government plays an important role in setting agendas, providing funding, and approving drugs for market. In 2007, the federal government allocated $300 million over three years to fund the HPV vaccine for girls (Guichon and Kaul 2015; Chantal 2015) . However, some anti-vaccination groups in Canada, such as Vaccine Choice Canada, continue to oppose HPV vaccine for both sexes.
Media. Sensational articles about HPV have been published in the Canadian media including
Macleans' cover story "Our girls are not guinea pigs", and the aforementioned Toronto Star's "A wonder drug's dark side", and Le Devoir's "Urgent call for a moratorium on HPV vaccination in Quebec" (Gulli, George, and Intini 2007; Bruser and Mclean 2015; Rail, Molino, and Lippman 2015) . Reading negative reports has been found to influence parents to refuse to vaccinate their children Gollust et al. 2010) .
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A 2009 content analysis of Canadian and U.S. national news coverage of HPV found that, in Canada, 28% of articles about the HPV vaccine were negative, whereas 43% were neutral and 29% were positive (Abdelmutti and Hoffman-Goetz 2009) . A 2016 Canadian content analysis, conducted after NACI's recommendation to vaccinate boys, found that the proportion of newspaper articles in Canada that mentioned HPV vaccination for boys significantly increased between 2012 and 2014; nevertheless, only half of all those articles discussed HPV vaccination for boys ).
Social media is another forum where HPV vaccination concerns can be voiced and circulated to Canadian audiences quickly. Sites such as Twitter quickly disseminate misinformation regarding HPV (Dunn et al. 2015) . Some research has evaluated online comments to news articles (Feinberg et al. 2015) , blogs or online discussion forums ( School boards. Because school aged children are typically vaccinated in school in Canada (Guichon et al. 2013) , school boards are a notable stakeholder in this debate. Soon after provinces announced HPV vaccination program for girls, some Roman Catholic bishops publicly discouraged HPV vaccination, encouraging "a proper education in chastity" (Wingle 2007 ) and abstinence (Smith et al. 2008) . Twelve school districts in Alberta, Ontario and the Northwest Territories banned the vaccine from being administered in publicly funded schools (Guichon et al. 2013 ). The HPV vaccine ban negatively affected HPV vaccination uptake because girls whose easy access was blocked by Catholic school boards were less likely to receive the vaccine than other girls. HPV vaccine bans caused particular hardship to girls with a lower socioeconomic status (Musto et al. 2013) . Because of advocacy which created pressure for the school trustees (Cotter 2014) , and the publication of Bednarcyk et al.'s (2012) A study by McClure et al. (2015) in P.E.I. found that students (girls and boys) in the English Language School Board were more than twice as likely as students in the French Language School Board to receive all three doses of the HPV vaccine (McClure et al. 2015) . Although the authors postulated that this finding is probably related to socio-demographic differences, more research is needed to examine the reasons that different linguistic school boards have varying HPV vaccine uptake (McClure et al. 2015) .
Discussion
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To date, few countries have publicly-funded HPV vaccination programs for boys: Australia Analysis from the Policy Stream identified that vaccinating boys is a suitable and equitable solution that has precedent in the universal female HPV vaccination program. While acceptability of HPV vaccination among boys in some provinces (e.g. P.E.I) appears strong, greater research is required to understand why provincial uptake varies. The most contentious factor has been cost-effectiveness analyses, which have varied depending on models and methodologies. Crucial to cost-effectiveness analyses is the vaccine price that provinces and territories negotiate with pharmaceutical companies, which is not public knowledge and inclusion of additional costs. Lowering vaccine costs through price negotiations and reducing
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delivery costs (by administering more than one vaccine at the same time) is a current priority to reach cost-effectiveness for male HPV vaccination (Baussano et al. 2014) . Indeed, Australia has obtained a lower vaccine price for males compared to females (Brotherton, Zuber, and Bloem 2016) . Moreover, the availability of funds also appears to have been crucial for policy change in some provinces. For example, P.E.I. appears to have had existing funds in the Department of Although Kingdon's MS framework offers a broad and multifaceted approach, it is not exhaustive. It would be useful for future research to evaluate other (high and low income)
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countries and conduct international comparisons, which necessitates taking into account the potential role of policy diffusion (Shipan and Volden, 2012) . It would also be helpful to extend this research by considering other policy frameworks that examine decision-making (Koon et al., 2013; Walt et al. 2008 ). For example, there is a burgeoning field examining how health policy systems research could be more directly embedded into the decision-making sphere (Koon et al., 2013) . The WHO and collaboration among National Immunization Technical Advisory Groups on immunization (NITAGs) are well positioned to lead improvements in the use of evidence in policy decision-making and make informed immunization decisions for their local contexts (Adjagba et al., 2015; Perronne et al., 2016) . Because there is little overlap in the decisionmaking processes of NITAGs (Nijsten et al., 2016; Ricciardi et al., 2015) , future research could inform the development of an international standard for an evidence-based process of decisionmaking for immunization policy. Such research should advance the conceptual decision-making framework for policy analysis.
Conclusion
As of March 2017, nine Canadian provinces offered, or intend soon to offer, publicly funded school-based HPV vaccination for males and females, albeit with slight variations. This paper's analysis identified that the interpretation of cost-effectiveness models, herd immunity 
